Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-11 of 11

Sort by

Sort Order Select

Journal Articles

High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers

Mol Cancer Ther (2019) 18 (10): 1696–1707.

https://doi.org/10.1158/1535-7163.MCT-18-1203

Published: 01 October 2019

View articletitled, High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers

Includes: Supplementary data

Journal Articles

Abstract B190: Pharmacokinetics of the AKT inhibitor CCT128930 from dried blood spots sampled from caudal bleeding compared with conventional cardiac puncture.

Florence I. Raynaud, Angela Hayes, Yasmin J. Asad, Louise Johnson, Alan T. Henley, John J. Caldwell, Ian Collins, Michelle D. Garrett

Mol Cancer Ther (2011) 10 (11_Supplement): B190.

https://doi.org/10.1158/1535-7163.TARG-11-B190

Published: 12 November 2011

View articletitled, Abstract B190: Pharmacokinetics of the AKT inhibitor CCT128930 from dried blood spots sampled from caudal bleeding compared with conventional cardiac puncture.

Journal Articles

Abstract A228: CCT244747 is a novel, potent and selective inhibitor of CHK1 with oral efficacy both alone in neuroblastoma and in combination with genotoxic chemotherapeutic agents.

Mol Cancer Ther (2011) 10 (11_Supplement): A228.

https://doi.org/10.1158/1535-7163.TARG-11-A228

Published: 12 November 2011

View articletitled, Abstract A228: CCT244747 is a novel, potent and selective inhibitor of CHK1 with oral efficacy both alone in neuroblastoma and in combination with genotoxic chemotherapeutic agents.

Journal Articles

Abstract A235: Structure-guided evolution of potent and selective oral inhibitors of CHK1 through scaffold morphing.

Mol Cancer Ther (2011) 10 (11_Supplement): A235.

https://doi.org/10.1158/1535-7163.TARG-11-A235

Published: 12 November 2011

View articletitled, Abstract A235: Structure-guided evolution of potent and selective oral inhibitors of CHK1 through scaffold morphing.

Journal Articles

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

Michael I. Walton, Paul D. Eve, Angela Hayes, Melanie Valenti, Alexis De Haven Brandon, Gary Box, Kathy J. Boxall, G. Wynne Aherne, Suzanne A. Eccles, Florence I. Raynaud, David H. Williams, John C. Reader, Ian Collins, Michelle D. Garrett

Mol Cancer Ther (2010) 9 (1): 89–100.

https://doi.org/10.1158/1535-7163.MCT-09-0938

Published: 12 January 2010

View articletitled, The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

Includes: Supplementary data

Journal Articles

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Mol Cancer Ther (2009) 8 (7): 1725–1738.

https://doi.org/10.1158/1535-7163.MCT-08-1200

Published: 14 July 2009

View articletitled, Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Includes: Supplementary data

Journal Articles

Cassette dosing in tumor bearing animals for the discovery of NVP-AUY922, a novel HSP90 inhibitor.

Florence Raynaud, Angela Hayes, Vanessa Martins, Nicola Smith, Swee Sharp, Melanie Valenti, Alan Henley, Thomas Matthews, Kwai-Ming Cheung, Andrew Kalusa, Keith Jones, Karen James, Edward McDonald, Paul Brough, Andrew Massey, Brian Dymock, Martin Drysdale, Suzanne Eccles, Paul Workman

Mol Cancer Ther (2007) 6 (11_Supplement): B289.

Published: 01 November 2007

View articletitled, Cassette dosing in tumor bearing animals for the discovery of NVP-AUY922, a novel HSP90 inhibitor.

Journal Articles

NVP-AUY922, a novel diarylisoxazole resorcinol HSP90 inhibitor, potently inhibits growth and metastasis of human tumor xenografts

Mol Cancer Ther (2007) 6 (11_Supplement): B284.

Published: 01 November 2007

View articletitled, NVP-AUY922, a novel diarylisoxazole resorcinol HSP90 inhibitor, potently inhibits growth and metastasis of human tumor xenografts

Journal Articles

Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

Mol Cancer Ther (2007) 6 (4): 1198–1211.

https://doi.org/10.1158/1535-7163.MCT-07-0149

Published: 12 April 2007

View articletitled, Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

Includes: Supplementary data

Journal Articles

Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors

Nicola F. Smith, Angela Hayes, Karen James, Bernard P. Nutley, Edward McDonald, Alan Henley, Brian Dymock, Martin J. Drysdale, Florence I. Raynaud, Paul Workman

Mol Cancer Ther (2006) 5 (6): 1628–1637.

https://doi.org/10.1158/1535-7163.MCT-06-0041

Published: 03 July 2006

View articletitled, Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors

Journal Articles

Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse

Bernard P. Nutley, Florence I. Raynaud, Stuart C. Wilson, Peter M. Fischer, Angela Hayes, Phyllis M. Goddard, Steven J. McClue, Michael Jarman, David P. Lane, Paul Workman

Mol Cancer Ther (2005) 4 (1): 125–139.

https://doi.org/10.1158/1535-7163.125.4.1

Published: 18 January 2005

View articletitled, Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers

Abstract B190: Pharmacokinetics of the AKT inhibitor CCT128930 from dried blood spots sampled from caudal bleeding compared with conventional cardiac puncture.

Abstract A228: CCT244747 is a novel, potent and selective inhibitor of CHK1 with oral efficacy both alone in neuroblastoma and in combination with genotoxic chemotherapeutic agents.

Abstract A235: Structure-guided evolution of potent and selective oral inhibitors of CHK1 through scaffold morphing.

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

Cassette dosing in tumor bearing animals for the discovery of NVP-AUY922, a novel HSP90 inhibitor.

NVP-AUY922, a novel diarylisoxazole resorcinol HSP90 inhibitor, potently inhibits growth and metastasis of human tumor xenografts

Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors

Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only